Effect of pharmacokinetic profile on the pancreatic toxicity and efficacy of tacrolimus in rats
スポンサーリンク
概要
- 論文の詳細を見る
The aim of this study is to investigate the effect of the pharmacokinetic profile of tacrolimus on its pancreatic toxicity and efficacy in rats. For toxicity evaluation, doses of 0.03, 0.1, or 0.3mg/kg/day were given once daily for 8 days in the bolus intravenous injection groups. In the continuous intravenous infusion groups, tacrolimus was infused using an Alzet^[○!R] osmotic mini-pump for 9 days at the same doses. Pancreatic insulin content decreased dose-dependently in both the bolus intravenous injection and continuous intravenous infusion groups, and there was no significant difference between the decreases caused by the two dosing regimens. At 0.03mg/kg, continuous intravenous infusion did not cause glucose intolerance, but bolus intravenous injection induced significant and dose-dependent glucose intolerance. The pharmacokinetic data indicated that continuous intravenous infusion resulted in a sustained blood drug concentration with an area under the curve (AUC) similar to that obtained with the bolus administration at the same dose. For efficacy evaluation, donor ear grafts were transplanted to the lateral thoraxes of recipients. Tacrolimus doses of 0.01, 0.1, or 1mg/kg/day were administered from day 0 to day 13. Both bolus intramuscular administration and continuous intravenous infusion prolonged skin allograft survival dose-dependently, and there was no significant difference between the median survival times of groups given the same doses. To summarize, the sustained-release of tacrolimus resulted in a steady blood drug concentration with an AUC similar to that of the bolus administration. In rats, it was better tolerated and just as efficacious as the bolus administration without producing a higher maximal blood concentration (Cmax). These results indicate that the sustained-release formulation has the potential to improve the safety of tacrolimus.
- 日本トキシコロジー学会の論文
- 2008-12-01
著者
-
Niwa Toshiro
Medical Science Research Astellas Pharma Inc.
-
Seki Jiro
Toxicologic Pathology Drug Safety Res. Laboratories Astellas Pharma Inc.
-
Mitamura Takashi
Drug Safety Research Laboratories, Astellas Pharma Inc.
-
Yamada Atsushi
Drug Safety Research Laboratories, Astellas Pharma Inc.
-
Hanaoka Kaori
Applied Pharmacology Research Laboratories, Astellas Pharma Inc.
-
Asano Masayuki
Medical Science Research, Astellas Pharma Inc.
-
Seki Jiro
Drug Safety Research Laboratories, Astellas Pharma Inc.
-
Mitamura Takashi
Drug Safety Res. Laboratories Astellas Pharma Inc.
-
Mitamura Takashi
Drug Safety Research Laboratories Astellas Pharma Inc.
-
Hanaoka Kaori
Applied Pharmacology Research Laboratories Astellas Pharma Inc.
-
Asano Masayuki
Medical Science Research Astellas Pharma Inc.
-
Yamada Atsushi
Drug Safety Res. Laboratories Astellas Pharma Inc.
-
Yamada Atsushi
Drug Safety Research Laboratories Astellas Pharma Inc.
関連論文
- TACROLIMUS (FK506)-INDUCED NEPHROTOXICITY IN SPONTANEOUS HYPERTENSIVE RATS
- Collaborative work on evaluation of ovarian toxicity : 12) Effects of 2- or 4-week repeated dose studies and fertility study of indomethacin in female rats
- MECHANISM OF FK506-INDUCED GLUCOSE INTOLERANCE IN RATS
- 新規なTi/(Pt+B2O3)被覆電極の作製とその特性
- Effect of Annealing Conditions on the Lifetime of Ta2O5-Pt Coated Titanium Electrodes (論文特集号 電解科学技術の進展)
- Effect of pharmacokinetic profile on the pancreatic toxicity and efficacy of tacrolimus in rats
- The optimized conditions for the in vitro micronucleus (MN) test procedures using chamber slides
- Inhibitory potency of tacrolimus ointment on skin tumor induction in a mouse model of an initiation-promotion skin tumor